Wendall Wierenga - Net Worth and Insider Trading

Wendall Wierenga Net Worth

The estimated net worth of Wendall Wierenga is at least $2 Million dollars as of 2024-04-27. Wendall Wierenga is the Director of Cytokinetics Inc and owns about 18,653 shares of Cytokinetics Inc (CYTK) stock worth over $1 Million. Wendall Wierenga is the Director of XenoPort Inc and owns about 28,998 shares of XenoPort Inc (XNPT) stock worth over $205,016. Wendall Wierenga is also the Director of Concert Pharmaceuticals Inc and owns about 12,389 shares of Concert Pharmaceuticals Inc (CNCE) stock worth over $103,696. Besides these, Wendall Wierenga also holds Ocera Therapeutics Inc (OCRX) . Details can be seen in Wendall Wierenga's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Wendall Wierenga has not made any transactions after 2023-12-27 and currently still holds the listed stock(s).

Transaction Summary of Wendall Wierenga

To

Wendall Wierenga Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Wendall Wierenga owns 8 companies in total, including Crinetics Pharmaceuticals Inc (CRNX) , Cytokinetics Inc (CYTK) , and Concert Pharmaceuticals Inc (CNCE) among others .

Click here to see the complete history of Wendall Wierenga’s form 4 insider trades.

Insider Ownership Summary of Wendall Wierenga

Ticker Comapny Transaction Date Type of Owner
CRNX Crinetics Pharmaceuticals Inc 2018-07-17 director
CYTK Cytokinetics Inc 2023-12-27 director
CNCE Concert Pharmaceuticals Inc 2018-06-14 director
SEEL Seelos Therapeutics Inc 2014-03-10 director
OCRX Ocera Therapeutics Inc 2017-12-11 director
XNPT XenoPort Inc 2016-07-05 director
ANAC Anacor Pharmaceuticals Inc 2016-06-24 director
NBIX Neurocrine Biosciences Inc 2005-02-18 EVP & Research & Development

Wendall Wierenga Latest Holdings Summary

Wendall Wierenga currently owns a total of 4 stocks. Among these stocks, Wendall Wierenga owns 18,653 shares of Cytokinetics Inc (CYTK) as of December 27, 2023, with a value of $1 Million and a weighting of 79.32%. Wendall Wierenga owns 28,998 shares of XenoPort Inc (XNPT) as of May 11, 2015, with a value of $205,016 and a weighting of 13.34%. Wendall Wierenga also owns 12,389 shares of Concert Pharmaceuticals Inc (CNCE) as of March 13, 2014, with a value of $103,696 and a weighting of 6.75%. The other 1 stocks Ocera Therapeutics Inc (OCRX) have a combined weighting of 0.58% among all his current holdings.

Latest Holdings of Wendall Wierenga

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CYTK Cytokinetics Inc 2023-12-27 18,653 65.34 1,218,787
XNPT XenoPort Inc 2015-05-11 28,998 7.07 205,016
CNCE Concert Pharmaceuticals Inc 2014-03-13 12,389 8.37 103,696
OCRX Ocera Therapeutics Inc 2015-06-23 5,000 1.79 8,950

Holding Weightings of Wendall Wierenga


Wendall Wierenga Form 4 Trading Tracker

According to the SEC Form 4 filings, Wendall Wierenga has made a total of 6 transactions in Cytokinetics Inc (CYTK) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Cytokinetics Inc is the sale of 10,000 shares on December 27, 2023, which brought Wendall Wierenga around $736,000.

According to the SEC Form 4 filings, Wendall Wierenga has made a total of 0 transactions in XenoPort Inc (XNPT) over the past 5 years. The most-recent trade in XenoPort Inc is the acquisition of 5,000 shares on May 11, 2015, which cost Wendall Wierenga around $28,150.

According to the SEC Form 4 filings, Wendall Wierenga has made a total of 0 transactions in Concert Pharmaceuticals Inc (CNCE) over the past 5 years. The most-recent trade in Concert Pharmaceuticals Inc is the sale of 0 shares on March 13, 2014, which brought Wendall Wierenga around $0.

More details on Wendall Wierenga's insider transactions can be found in the Insider Trading History of Wendall Wierenga table.

Insider Trading History of Wendall Wierenga

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Wendall Wierenga Trading Performance

GuruFocus tracks the stock performance after each of Wendall Wierenga's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Wendall Wierenga is 7.48%. GuruFocus also compares Wendall Wierenga's trading performance to market benchmark return within the same time period. The performance of stocks bought by Wendall Wierenga within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Wendall Wierenga's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Wendall Wierenga

Average Return

-37.95%

Average return per transaction

Outperforming Transactions

0%

0 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 11.71 7.48 8.74 -37.95 -47.48
Relative Return to S&P 500(%) 12.14 12.35 10.87 -36.73 -54.61

Wendall Wierenga Ownership Network

Ownership Network List of Wendall Wierenga

No Data

Ownership Network Relation of Wendall Wierenga


Wendall Wierenga Owned Company Details

What does Crinetics Pharmaceuticals Inc do?

Who are the key executives at Crinetics Pharmaceuticals Inc?

Wendall Wierenga is the director of Crinetics Pharmaceuticals Inc. Other key executives at Crinetics Pharmaceuticals Inc include Chief Development Officer Dana Pizzuti , director & See Remarks Richard Scott Struthers , and Chief Operating Officer Jeff E. Knight .

Crinetics Pharmaceuticals Inc (CRNX) Insider Trades Summary

Over the past 18 months, Wendall Wierenga made no insider transaction in Crinetics Pharmaceuticals Inc (CRNX). Other recent insider transactions involving Crinetics Pharmaceuticals Inc (CRNX) include a net sale of 42,092 shares made by Stephen F. Betz , a net sale of 61,634 shares made by Dana Pizzuti , and a net sale of 340,951 shares made by Richard Scott Struthers .

In summary, during the past 3 months, insiders sold 187,216 shares of Crinetics Pharmaceuticals Inc (CRNX) in total and bought 0 shares, with a net sale of 187,216 shares. During the past 18 months, 619,400 shares of Crinetics Pharmaceuticals Inc (CRNX) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 614,400 shares.

Crinetics Pharmaceuticals Inc (CRNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Crinetics Pharmaceuticals Inc Insider Transactions

No Available Data

Wendall Wierenga Mailing Address

Above is the net worth, insider trading, and ownership report for Wendall Wierenga. You might contact Wendall Wierenga via mailing address: 12790 El Camino Real, C/o Neurocrine Biosciences, San Diego Ca 92130.

Discussions on Wendall Wierenga

No discussions yet.